Weak Pipeline Unlikely to Drive the Growth of Aplastic Anemia Market

Wednesday 18 April 2012, Amsterdam

Weak Pipeline Unlikely to Drive the Growth of Aplastic Anemia Market
The “Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019” report is an essential source of information and analysis on the global aplastic anemia therapeutics market. The report identifies the key trends shaping and driving the global aplastic anemia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global aplastic anemia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Market is Forecast to Show Slow Growth until 2019

The report estimates that the global aplastic anemia therapeutics market was worth $73.3m in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.1% to reach $79.7m by 2019. The current treatment options for aplastic anemia include allogeneic stem cell transplant and immunosuppressive therapy which are primarily dominated by generics. There is no promising, industry-sponsored molecule in the late stage pipeline. Owing to these factors, the aplastic anemia market is expected to show slow growth until 2019.

The Aplastic Anemia Market has Moderate Unmet Need

Current treatment options for aplastic anemia are allogeneic stem cell transplant or immunosuppressive therapy. Although these therapies are effective in approximately 70% of patients, stem cell transplant is associated with the risk of developing graft failure and graft-versus-host disease (GVHD). Chances of relapse and further development to myelodysplastic syndrome (MDS) limit the use of immunosuppressive therapy. Therefore, a moderate unmet need exists in the treatment of aplastic anemia.

Scope for Entrants with Better Efficacy and Safety Profiles

The aplastic anemia market is moderately served by the currently marketed products as these are effective only in approximately 70% of patients, and are associated with serious complications and relapses. Therefore, the aplastic anemia market offers adequate opportunity for new entrants who can develop drugs that can reduce the chances of graft rejection, GVHD and relapses, together with better efficacy and safety profiles.

Weak Pipeline Unlikely to Drive the Growth of Aplastic Anemia Market

This analysis of the entire pipeline landscape shows that the late stage pipeline does not offer any immediate hope for aplastic anemia patients. There is no molecule in Phase III of development. The only molecule in Phase II/III is alemtuzumab. Alemtuzumab is under investigation as a conditioning regimen for patients with severe aplastic anemia who are undergoing allogeneic stem cell transplantation using matched unrelated donors and mismatched related donors, which is a very small set of patients. The trial is sponsored by the Mayo Clinic. Eltrombopag, which is currently under Phase II development, may give some hope for aplastic anemia patients and could be launched by 2018, driving the growth of the aplastic anemia market. This trial was initiated by the National Heart, Lung, and Blood Institute (NHLBI) in March 2011.
Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Publish date : February 2012
Report code : ASDR-27802
Pages : 65

ASDReports.com contact: S. Koomen

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216

 back to News